Quantum Biopharma (NASDAQ:QNTM) Lowered to Strong Sell Rating by Wall Street Zen

Quantum Biopharma (NASDAQ:QNTM) was downgraded by stock analysts at Wall Street Zen from a “sell” rating to a “strong sell” rating in a research report issued on Saturday.

Separately, Weiss Ratings downgraded Quantum Biopharma from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, May 28th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company currently has an average rating of “Sell”.

Quantum Biopharma Price Performance

Shares of NASDAQ:QNTM opened at $3.24 on Friday. Quantum Biopharma has a fifty-two week low of $2.07 and a fifty-two week high of $31.91. The business has a 50-day moving average of $4.77 and a two-hundred day moving average of $4.61. The stock has a market capitalization of $20.74 million, a P/E ratio of -0.39 and a beta of 0.43.

Institutional Trading of Quantum Biopharma

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Platform Technology Partners acquired a new stake in Quantum Biopharma in the 1st quarter valued at approximately $199,000. Jane Street Group LLC acquired a new position in shares of Quantum Biopharma during the fourth quarter worth approximately $80,000. Finally, Virtu Financial LLC acquired a new position in shares of Quantum Biopharma during the fourth quarter worth approximately $76,000. Institutional investors and hedge funds own 1.24% of the company’s stock.

Quantum Biopharma Company Profile

Quantum Biopharma Ltd. is a biotechnology pharmaceutical research and development company, which focuses on the cultivation, process, and sale of medical cannabis. It operates through the Biotechnology and Strategic Investments segments. The Biotechnology segment is involved in the research and development of the company’s three drug candidates consisting of FSD-PEA, Lucid-PSYCH, and Lucid-MS. The Strategic Investments segment is focused on generating returns and cashflow through the issuance of loans secured by residential or commercial property.